BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1347 related articles for article (PubMed ID: 15452182)

  • 41. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
    Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
    Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
    Fisher B; Redmond C
    J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
    Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
    Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
    Shen K; Shen Z; Han Q
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):221-4. PubMed ID: 10920903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
    Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
    J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
    Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
    J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of postoperative radiotherapy in node negative breast cancer patients with pT3-T4 disease.
    Aksu G; Kucucuk S; Fayda M; Saynak M; Baskaya S; Saip P; Ozturk N; Aslay I
    Eur J Surg Oncol; 2007 Apr; 33(3):285-93. PubMed ID: 17145158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.
    Recht A; Gray R; Davidson NE; Fowble BL; Solin LJ; Cummings FJ; Falkson G; Falkson HC; Taylor SG; Tormey DC
    J Clin Oncol; 1999 Jun; 17(6):1689-700. PubMed ID: 10561205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can the addition of regional radiotherapy counterbalance important risk factors in breast cancer patients with extracapsular invasion of axillary lymph node metastases?
    Gruber G; Berclaz G; Altermatt HJ; Greiner RH
    Strahlenther Onkol; 2003 Oct; 179(10):661-6. PubMed ID: 14566473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of subcutaneous mastectomy with radical mastectomy.
    Horiguchi J; Iino JHY ; Takei H; Koibuchi Y; Iijima K; Ikeda F; Ochiai R; Uchida K; Yoshida M; Yokoe T; Morishita Y
    Anticancer Res; 2001; 21(4B):2963-7. PubMed ID: 11712794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.